Clinical Research Trials : Nonalcoholic Fatty Liver Diseases (NASH)

Nonalcoholic Fatty Liver Diseases (NASH)

1. MB130-068: A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults with Nonalcoholic Steatohepatitis
(NASH) and Stage 3 Liver Fibrosis

  • Status: Open
  • PI: Dr. Eugene Schiff
  • Coordinator: Odalys Rodriguez
  • Contact: (305) 243-4648 / obravo@med.miami.edu

2. MB130-069: A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults with Nonalcoholic Steatohepatitis
(NASH) and Compensated Liver Cirrhosis

  • Status: Open
  • PI: Dr. Eugene Schiff
  • Coordinator: Odalys Rodriguez
  • Contact: (305) 243-4648 / obravo@med.miami.edu

3. Saro.16.005: A Phase 2, Prospective, Multicenter, Double-Blind, Randomized Study of Saroglitazar Magnesium 1 mg, 2 mg, or 4 mg, Versus Placebo in Patients with Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis

  • Status: Open
  • PI: Dr. Eugene Schiff
  • Coordinator: Diane Sabogal
  • Contact: (305) 243-1501 / d.sabogal@med.miami.edu

4. Tobira 3152-301-002: AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis

  • Status: Open
  • PI: Dr. Kalyan Bhamidimarri
  • Coordinator: Andrea Elibero
  • Contact: (305) 243-6968 / axe375@med.miami.edu

5. Genfit: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with NASH and fibrosis

  • Status: Open
  • PI: Dr. Eugene Schiff
  • Coordinator: Andrea Elibero
  • Contact: (305) 243-6968 / axe375@med.miami.edu

6. Intercept 747-303: Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, to Evaluate Obeticholic Acid in Subjects with NASH

  • Status: Open
  • PI: Dr. Eugene Schiff
  • Coordinator: Andrea Elibero
  • Contact: (305) 243-6968 / axe375@med.miami.edu

7. Intercept 747-304: A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis

  • Status: Open
  • PI: Dr. Eugene Schiff
  • Coordinator: Odalys Rodriguez
  • Contact: (305) 243-4648 / obravo@med.miami.edu

8. HQ-US-SHUNT-1701: The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Functioning and Physiology

  • Status: Open
  • PI: Dr. Kalyan Bhamidimarri
  • Coordinator: Diane Sabogal
  • Contact: (305) 243-1501 / d.sabogal@med.miami.edu

9. GS-US-454-4378: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects with Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH)

  • Status: Open
  • PI: Dr. Eugene Schiff
  • Coordinator: Lourdes Onate
  • Contact: (305) 243-6939 / malourdeso@med.miami.edu

10. CLJN452A2202: A Randomized, Double-Blind, Placebo Controlled, 2- part, Adaptive Design, Multicenter 12-week Study to Assess Safety, Tolerability and Efficacy of LJN452 in Patients with Non-alcoholic Steatohepatitis (NASH)

  • Status: Open
  • PI: Dr. Eugene Schiff
  • Coordinator: Andrea Elibero
  • Contact: (305) 243-6968 / axe375@med.miami.edu

11. Conatus IDN-6556-17: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis

  • Status: Open
  • PI: Dr. Kalyan Bhamidimarri
  • Coordinator: Tiffannia Grant
  • Contact: (305) 243-4649 / t.grant11@med.miami.edu